We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eli Lilly announced on Sep. 4 that its new psoriasis drug: ixekizumab (Taltz®) had entered China and passed the marketing approval of the NMPA, which is another blockbuster psoriasis drug approved following the approval of the “first-in-class” new drug be